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Introduction: Drug-target binding kinetics are major determinants of the
time course of drug action for several drugs, as clearly described for the
irreversible binders omeprazole and aspirin. This supports the increasing
interest to incorporate newly developed high-throughput assays for drug-
target binding kinetics in drug discovery. A meaningful application of in vitro
drug-target binding kinetics in drug discovery requires insight into the rela-
tion between in vivo drug effect and in vitro measured drug-target binding
kinetics.
Areas covered: In this review, the authors discuss both the relation between
in vitro and in vivo measured binding kinetics and the relation between in
vivo binding kinetics, target occupancy and effect profiles.
Expert opinion: More scientific evidence is required for the rational selection
and development of drug-candidates on the basis of in vitro estimates of
drug-target binding kinetics. To elucidate the value of in vitro binding
kinetics measurements, it is necessary to obtain information on system-
specific properties which influence the kinetics of target occupancy and
drug effect. Mathematical integration of this information enables the iden-
tification of drug-specific properties which lead to optimal target occupancy
and drug effect in patients.
Keywords: drug-target binding kinetics, endogenous competition, in vitro, in vivo, mechanistic,
nonspecific binding, patients, PKPD modeling, rebinding, target turnover
Expert Opin. Drug Discov. (2016) 11(1):45-63
1. Introduction
The rates of drug-target association and dissociation are essential determinants of
the time course of target binding and drug effect. This is most clearly illustrated by
the irreversible binders aspirin and omeprazole, which have shown a long-lasting
effect in clinical practice.[1–3] Numerous other examples confirm that drug-target
binding kinetics are important drug characteristics, as reviewed by others.[4–6]
The relevance of drug-target binding arises from their connecting role between
pharmacokinetics and pharmacodynamics. More precisely, for a given drug con-
centration profile, the kinetics of drug-target binding determine the time course of
target occupancy and thus the time course of drug effect. The basic concepts of
target equilibration kinetics are well established. The simplest mechanism to
describe drug-target binding is depicted in Equation 1:
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in which T is the target concentration, L is the ligand con-
centration, kon is the second-order association rate constant
and koff is the first-order dissociation rate constant. However,
more complex mechanisms have been described in which
target activation and G-protein coupled receptors (GPCRs)
are incorporated.[5,7] Affinity, the ratio of the dissociation
and association rate constants (KD = koff/kon), is related to
binding kinetics, but informs only on the extent of binding
at equilibrium and gives no information on the required time
to reach a new equilibrium.
The important role of drug-target binding kinetics as a
determinant of target occupancy profiles has been known for
long, and both in vitro and in vivo measurements of associa-
tion and dissociation kinetics have been reported from the
1980s.[8–10] However, with the development of high-
throughput in vitro methods for binding kinetics, such as
surface plasmon resonance (SPR), the interest in the use of
binding kinetics in drug discovery has been rising in the past
10 years. This has also led to the development of structure–
kinetics relationships (SKRs) for some drug classes.[11,12]
The recent attention for binding kinetics in drug discovery
focuses mostly on the drug-target dissociation rate, since a
slow dissociation rate is expected to give a prolonged dura-
tion of drug action and improved efficacy.[5,6,13–16]
While most recent publications express an expected benefit
of incorporating drug-target binding kinetics in drug discov-
ery, more critical studies have also been published. On the
basis of basic pharmacokinetic/pharmacodynamic simula-
tions, Dahl and Akerud indicated that the relevance of bind-
ing kinetics in drug treatment depends on a drug’s
pharmacokinetics.[15] Several other studies have indicated
that multiple other physiological processes can influence the
impact of drug-target binding kinetics on drug effect, includ-
ing endogenous competition, diffusion-limited binding and
signal transduction.[17–19] While these simulations might
contain oversimplifications and cannot be applied to all cases
of drug treatment, it is important to realize that the impact of
drug-target binding kinetics on drug action depends on
multiple kinetic processes in the human body.
To incorporate the role of drug-target binding kinetics in
this complexity of kinetic processes, mathematical models
have been developed to describe and predict the time profile
of drug effects for several drugs and targets.[20–26] These
models have been used to estimate drug-target binding
kinetics on basis of pharmacokinetic and pharmacodynamic
data, which support the relevance of drug-target binding
kinetics for drug action.
In summary, the available literature indicates a growing
interest in the application of screening techniques for binding
kinetics in drug discovery and a context dependency for the
impact of drug-target binding kinetics on drug effect. This
poses the question under which conditions the in vitro
screening of binding kinetics would further drug discovery
and development. To answer this question, this review aims
to investigate the value of in vitro binding kinetics measure-
ments for the prediction of in vivo target occupancy and drug
effect, using available literature with emphasis on two
questions:
● What is the relation between in vitro measured binding
kinetics and in vivo measured binding kinetics?
● To what extent do binding kinetics contribute to target
occupancy and drug effect profiles in vivo?
To that end, first, the available methods to measure drug-
target binding kinetics both in vitro and in vivo are addressed
and discussed. Second, we discuss to what extent the esti-
mates of these in vitro and in vivo methods provide compar-
able results, and what experimental conditions are required to
enable translation of in vitro to in vivo binding kinetics.
Third, we discuss binding kinetics in a broader perspective,
i.e. in the context of the other determinants of target occu-
pancy and drug effect. Finally, the integration of all kinetic
processes is discussed, as well as their implementation in the
various phases of drug discovery and development.
2. In vitromethodological approaches tomeasure
binding kinetics
2.1. Labeled-ligand assays
Various methods are available to determine in vitro kinetic
binding parameters of compounds of interest at their respec-
tive target. In this review, we will use “ligand” to refer to
compounds of interest (either labeled or unlabeled) and we
will use “tracer” to refer to labeled or unlabeled compounds
with known binding characteristics intended to inform about
the binding of compounds of interest. The methods as dis-
cussed below are summarized in Table 1.
Article highlights.
● New in vitro methods for measurement of drug-target
binding kinetics to enable their use in drug discovery.
● Various in vitro and in vivo measurement methods of
binding kinetics are available, but their validity is not well
defined.
● Compared dissociation rate constant values from in vitro
and in vivomeasurements reveal inconsistent discrepancies.
● These discrepancies can be expected from the unac-
counted presence of other kinetic factors in both in
vivo and in vitro experiments.
● Mechanistic models can account for these processes to
analyze and predict the impact of drug-target binding
kinetics on drug effect.
This box summarizes key points contained in the article.
DeWitte et al.
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2.1.1. Radiolabel-based assays
The most commonly used and straightforward method to
characterize target binding is the use of radioligand binding
assays. These assays use a radiolabeled ligand and can directly
measure the association and dissociation rates of the radiola-
beled ligand. In addition to traditional association and dis-
sociation experiments, other kinetic radiolabel-based binding
assays such as a competition association assay are emerging.
This type of assay is an indirect assay based on a theoretical
model developed by Motulsky and Mahan in 1984 by which
one can quantitatively determine the binding kinetics of
unlabeled ligands in a competitive assay using only one
radiotracer.[16,27–29] The competition association assay
can also be used in a higher-throughput fashion with the
recently developed dual-point competition association assay.
Only two time points are selected here to measure radiotracer
binding; the ratio of binding at both time points gives a
qualitative measure of the ligands’ dissociation kinetics.
This makes this simplified assay a suitable method for screen-
ing potential drug candidates with favorable dissociation
kinetics.[30]
2.1.2. Fluorescent label-based assays
Similarly, instead of using a radiolabeled tracer in a competi-
tion assay the tracer can also be fluorescently labeled and used
in homogeneous time-resolved fluorescence (HTRF) assays.
Similar to the radioligand competition assay, only one fluor-
escently labeled tracer is required and the binding kinetics of
competitive ligands can be determined in an indirect fashion.
This method is homogeneous since it requires no physical
separation of bound and free ligand which enables continu-
ous measurements and increases the throughput. HTRF
assays are successfully applied in the determination of bind-
ing kinetics of dopamine D2 receptor antagonist spiperone
[31] and more recently for histamine H1 receptor ligands
[32] and GnRH receptor agonists.[33] Of note, in addition
to a fluorescently labeled tracer a fluorescently labeled recep-
tor is needed for this method, as opposed to wild-type
receptors for radioligand and radiotracer binding.
2.2. Label-free assays
Several label-free methods can be applied for kinetic target
binding measurements without the need of a labeled ligand
or labeled tracer.
2.2.1. Surface plasmon resonance
The most instilled label-free measurement is SPR spectro-
scopy.[34] This method has the potential to be medium-
throughput and the capability to measure real-time quanti-
tative binding kinetics of ligands for membrane proteins
using relatively small quantities of protein. The traditional
SPR method needs one immobilized binding component on
a coated gold sensor chip during which the ligand in solution
is flowed over the sensor chip. This induces a real-timeTa
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change in the refractive index on the sensor surface which is
linear to the number of molecules bound.[34–36]
2.2.2. Acoustic wave biosensor
Another label-free technology is the surface acoustic wave
biosensor.[37] This methodology captures real-time mass
changes on the surface, which result in a shifted phase and/
or changed amplitude of a sound wave signal.[38] A disad-
vantage of these biophysical approaches for G protein-
coupled receptors is that these receptors are integral mem-
brane proteins that rapidly disintegrate when taken out of
their natural environment, which is a prerequisite for these
approaches. However, recent advances are made to overcome
this problem.[34]
2.3. Functional assays
Another way to determine drug-target binding kinetics is
by use of functional assays. These assays provide an indir-
ect measurement of binding kinetics by characterizing the
time profile of drug effect. Although the use of functional
assays is generally limited due to the indirect nature of
these measurements, functional assays are valuable for the
measurement of enzyme binding kinetics because of the
direct relation between enzymatic product generation rates
and enzyme inhibitor binding. Functional assays can be
carried out in two different settings, either by resembling
the classical “organ bath” experiment or by washout
experiments.
2.3.1. Organ bath
An organ bath experiment is only suitable to qualitatively
examine binding kinetics of antagonists and requires pre-
incubation of cells/tissues with antagonists prior their chal-
lenge with an agonist. With this method the distinction
between so-called surmountable and insurmountable antago-
nists can be made, where the level of insurmountability by an
antagonist is related to its receptor dissociation kinetics.
[18,39,40]
2.3.2. Washout
Functional washout experiments are suitable for predicting
binding kinetics of both agonists and antagonists. In these
types of experiments, the rate of decrease in effect after
removal of the free ligand by repeated washing (washout) is
measured. Agonists with fast dissociation kinetics will readily
wash out and will show a right-ward shift in their potency,
whereas agonists with slow dissociation kinetics will show
insignificant shifts in their potency, and vice versa for antago-
nists. It should be stated that control experiments are neces-
sary to confirm that the long-lasting effect of the ligand is
due to long target binding versus other effect-prolonging
factors (such as exosite binding, membrane partitioning,
rebinding or signal transduction).[41–43]
3.1. In vivomethodological approaches to measure
binding kinetics
3.1.1. General principle of target occupancy
measurements
To obtain drug-target binding kinetics in vivo, target occu-
pancy and target site concentrations are required. For most in
vivo and ex vivo approaches, the target occupancy of a drug is
measured indirectly by using a tracer. The administered drug
competes at the same target site with the tracer and the
reduction in specific binding of the tracer is used to calculate
the target occupancy of the drug. The tracer can be an
antagonist (more common) or agonist to the target, and
can be radiolabeled (more common) or non-radiolabeled.
The advantages and disadvantages of each approach are
briefly discussed, and the characteristics of each approach
are summarized in Table 2. We focus here mainly on meth-
ods which are in use for measurement of binding kinetics in
the brain, since most methods have been used primarily for
the brain targets.
3.1.2. Tissue homogenate method with radiolabeled
tracer
The traditional way of measuring CNS target occupancy in
preclinical animals is the brain homogenate method. At a
predetermined time point after radiotracer administration,
the animal is sacrificed and the brain regions of interest (e.g.
striatum for D2 receptors) and the reference region (e.g. cere-
bellum which has relatively low D2 receptor density, for the
correction of nonspecific binding of radiotracer to and uptake
in brain tissue) are collected. These brain regions are then
dissolved in a scintillation cocktail and the drug-induced
change in radioactivity of the tracer is measured by a liquid
scintillation counter. Literature reports suggest that the target
occupancy values obtained by this method are comparable to
that obtained by positron emission tomography (PET) ima-
ging.[44] Compared with PET/SPECT (single-photon emis-
sion computed tomography) imaging, this method is
associated with much lower costs and allows higher through-
put in screening different compounds or different doses of a
single compound. Nevertheless, since this method involves the
terminal use of animals, a continuous target occupancy time
profile within the same animal cannot be obtained, and multi-
ple animals are needed for a single target occupancy time
profile. Moreover, in addition to the receptors expressed on
the membrane surface, intracellular or internalized receptors
would also become accessible to the tracer when the tissue is
homogenized, which might hamper the accuracy of target
occupancy assessment for membrane-bound receptors.[45]
3.1.3. Tissue homogenate method with non-
radiolabeled tracer using LC/MS assays
The procedures of this method are the same as that with
radiolabeled tracer as described above, except that a non--
radiolabeled tracer (cold tracer) is administered to the animal
DeWitte et al.
48 Expert Opin. Drug Discov. (2016) 11(1)
Ta
b
le
2.
O
ve
rv
ie
w
o
f
in
/e
x
vi
vo
m
et
h
o
d
s
to
m
ea
su
re
d
ru
g
-t
ar
g
et
b
in
d
in
g
ki
n
et
ic
s.
In
vi
vo
m
et
h
o
d
s
Ex
vi
vo
m
et
h
o
d
s
Te
ch
ni
qu
e
PE
T
sc
an
SP
EC
T
sc
an
Be
ta
-m
ic
ro
pr
ob
e
Ti
ss
ue
ho
m
og
en
at
e
m
et
ho
d
w
ith
ra
di
ol
ab
el
ed
tr
ac
er
Ti
ss
ue
ho
m
og
en
at
e
m
et
ho
d
w
ith
no
n-
ra
di
ol
ab
el
ed
tr
ac
er
Si
ng
le
tim
e-
po
in
t,
tis
su
e
ho
m
og
en
at
e
m
et
ho
d
w
ith
ra
di
ol
ab
el
ed
tr
ac
er
Si
ng
le
tim
e-
po
in
t,
tis
su
e
sl
ic
e
m
et
ho
d
w
ith
au
to
ra
di
og
ra
ph
y
im
ag
in
g
Su
bj
ec
ts
Li
vi
ng
hu
m
an
s
or
an
im
al
s
Li
vi
ng
hu
m
an
s
or
an
im
al
s
Li
vi
ng
an
im
al
s
A
ni
m
al
s
sa
cr
ifi
ce
d
at
a
sp
ec
ifi
c
po
st
-d
ru
g
do
si
ng
tim
e
po
in
t
A
ni
m
al
s
sa
cr
ifi
ce
d
at
a
sp
ec
ifi
c
po
st
-d
ru
g
do
si
ng
tim
e
po
in
t
A
ni
m
al
s
sa
cr
ifi
ce
d
at
a
sp
ec
ifi
c
po
st
-d
ru
g
do
si
ng
tim
e
po
in
t
A
ni
m
al
s
sa
cr
ifi
ce
d
at
a
sp
ec
ifi
c
po
st
-d
ru
g
do
si
ng
tim
e
po
in
t
Eq
ui
pm
en
t
C
yc
lo
tr
on
s
an
d
PE
T
sc
an
ne
r
SP
EC
T
sc
an
ne
r
Po
si
tr
on
-s
en
si
tiv
e
pr
ob
e
Sc
in
til
la
tio
n
co
un
te
r
Li
qu
id
ch
ro
m
at
og
ra
ph
/m
as
s
sp
ec
tr
om
et
er
Sc
in
til
la
tio
n
co
un
te
r
A
ut
or
ad
io
gr
ap
hi
c
fil
m
,
st
or
ag
e
ph
os
ph
or
im
ag
er
or
be
ta
-im
ag
er
Ra
di
ol
ab
el
ed
tr
ac
er
ne
ed
ed
?
Y
es
Y
es
Y
es
Y
es
N
o
Y
es
Y
es
Si
m
ul
ta
ne
ou
s
TO
de
te
rm
in
at
io
n
fo
r
m
ul
tip
le
re
ce
pt
or
s?
D
iff
ic
ul
t
Y
es
N
o
N
o
Y
es
N
o
Y
es
Re
la
tio
n
to
dr
ug
bi
nd
in
g
ki
ne
tic
s
In
fe
rr
ed
fr
om
tr
ac
er
bi
nd
in
g
In
fe
rr
ed
fr
om
tr
ac
er
bi
nd
in
g
In
fe
rr
ed
fr
om
tr
ac
er
bi
nd
in
g
In
fe
rr
ed
fr
om
tr
ac
er
bi
nd
in
g
fr
om
m
ul
tip
le
tis
su
e
sa
m
pl
es
In
fe
rr
ed
fr
om
tr
ac
er
bi
nd
in
g
fr
om
m
ul
tip
le
tis
su
e
sa
m
pl
es
In
fe
rr
ed
fr
om
tr
ac
er
bi
nd
in
g
fr
om
m
ul
tip
le
tis
su
e
sa
m
pl
es
In
fe
rr
ed
fr
om
tr
ac
er
bi
nd
in
g
fr
om
m
ul
tip
le
tis
su
e
sa
m
pl
es
M
aj
or
co
nf
ou
nd
in
g
fa
ct
or
s
A
ne
st
he
si
a,
tr
ac
er
m
et
ab
ol
ite
in
te
rf
er
en
ce
A
ne
st
he
si
a,
tr
ac
er
m
et
ab
ol
ite
in
te
rf
er
en
ce
Ti
ss
ue
da
m
ag
e,
tr
ac
er
m
et
ab
ol
ite
in
te
rf
er
en
ce
Tr
ac
er
do
se
,
do
si
ng
tim
e
of
tr
ac
er
,
tr
ac
er
m
et
ab
ol
ite
Tr
ac
er
do
se
,
do
si
ng
tim
e
of
tr
ac
er
Tr
ac
er
in
cu
ba
tio
n
pe
rio
d
an
d
te
m
pe
ra
tu
re
Tr
ac
er
in
cu
ba
tio
n
pe
rio
d
an
d
te
m
pe
ra
tu
re
PE
T:
Po
si
tr
on
em
is
si
on
to
m
og
ra
ph
y;
SP
R:
Su
rf
ac
e
pl
as
m
on
re
so
na
nc
e;
SP
EC
T:
Si
ng
le
ph
ot
on
em
is
si
on
co
m
pu
te
d
to
m
og
ra
ph
y;
TO
:
Ta
rg
et
oc
cu
pa
nc
y.
Rational use of in vitro drug-target binding kinetics
Expert Opin. Drug Discov. (2016) 11(1) 49
and the absolute amount of the tracer in the brain tissues is
quantified by LC/MS. The first report was presented by
Phebus and colleagues, in which the drug-induced target
occupancy of D2, serotonin 2A and NK-1 receptors in rat
was quantified using non-radiolabeled tracers.[46] They also
demonstrated in rats that for the eight D2-antagonists they
had investigated, the doses required to achieve 50% target
occupancy using this LC/MS method (cold raclopride as
tracer) are comparable to those using the traditional brain
homogenate method ([3H]raclopride as tracer).[47] This
method offers several advantages; first, the parent, intact
tracer in the brain tissue can be differentiated from the tracer
metabolites, thus increasing the accuracy of tracer quantifica-
tion. Second, the costs and hazards associated with radio-
activity are avoided. Third, it allows separation and
quantification of different tracers in one sample, and thus
enables the simultaneous assessment of the target occupancy
of different receptors.[48]
The greatest concern of this method is the relatively high
dose of the tracer that needs to be administered. Since the
sensitivity of an LC/MS assay is lower than that of radio-
activity counting, a much higher dose of the tracer is admi-
nistered in order to achieve a quantifiable tissue
concentration. This high tracer dose might distort the drug-
induced target occupancy and might exert pharmacody-
namics effects.[49,50]
3.1.4. PET/SPECT imaging
PET and SPECT imaging are the most common approaches
to measure drug target occupancy in living humans and other
primates. After the administration of a very small dose of
radiotracer for the desired target, scans are carried out by the
PET or SPECT scanner before and after administration of
the competing drug. The radioactivity at the region of inter-
est is measured, from which the density of receptors (Bmax)
and the radiotracer binding affinity (KD) are derived. The
ratio of Bmax and KD is termed the binding potential. The
target occupancy of the drug is calculated as the percentage
reduction in binding potential after drug administration.
Binding kinetic parameters (kon, koff) can be derived if the
target occupancy and free drug PK at the binding site are
available by fitting a mathematical model which describes
binding kinetics according to Scheme 1. However, the PET
signal arises from the sum of free, specifically and nonspeci-
fically bound radiotracer, and free concentrations cannot be
measured at the binding site. Instead of the free drug phar-
macokinetics at the binding site, a reference tissue which is
similar to the binding site but has no specific binding is
commonly used.[51,52] PET/SPECT can be regarded as an
in vivo version of autoradiography (discussed in Section 3.2),
with inferior spatial resolution but with the advantage that
the pharmacokinetics of the tracer can be measured in a
single experiment, or even in repeated studies on the same
subject.[53] This also provides the possibility to obtain target
occupancy values at different time points within the same
subject. Over the past decade, there are considerable devel-
opments of both PET and SPECT systems with improved
spatial resolution designed specifically for small-animal ima-
ging (i.e. microPET and microSPECT).
A limiting factor in longitudinal PET/SPECT measure-
ments is the half-life of the radioactive decay of the tracer
(depending on the applied radiolabel), which can limit the
duration of the experiment after tracer administration. This
limited duration of the imaging decreases the suitability of
PET/SPECT for measuring drugs with slow binding kinetics.
One of the main concerns in PET/SPECT is that the
anesthesia, applied to immobilize the animals before and
during imaging, could hamper the accuracy of target occu-
pancy assessment by, for example, altering the level of neu-
rotransmitters.[54] Moreover, the use of anesthesia might
also impose additional experimental variability (e.g. due to
variable susceptibility to the anesthetic effect [55]).
Since both the tracer and the drug of interest interact with
the same receptor, the observed effect cannot be completely
attributed to the drug. Therefore, drug effect measurements
are considered less useful, except for studies which are
focused on the binding and effect of only the tracer.
Depending on the target of interest, the required anesthesia
can also interact with drug effects and make their measure-
ment impossible or less useful. Alternatively, the drug effect
might be evaluated just before the administration of the
tracer (and anesthetics).
3.1.5. Beta-microprobe
Another method of measuring a radiotracer in a living ani-
mal’s brain is the use of a beta-microprobe. The microprobe
captures beta/positron emission (similar to the PET detector)
and is surgically implanted in the brain structures of interest,
allowing in vivo measurement of local radioactivity concen-
trations within 1 – 2 mm from the probe. Reports on the
application of beta-microprobe on target occupancy assess-
ment are limited. Good correlations have been reported
between in vivo beta-microprobe measurements and ex vivo
brain homogenate and in vivo microPET measurements of
respectively D2 and 5HT1A target occupancy in rat brain.
[56,57]
The potential advantages of beta-microprobe are that the
target occupancy could be measured in awake, non-anesthe-
tized animals and simultaneous assessment of drug-induced
changes in behavior is allowed, which are critical for drugs
that act on CNS receptors. Nevertheless, the surgical implan-
tation procedures might interfere with the neurochemistry
and the pharmacokinetics and pharmacodynamics of the
drug and tracer. Implantation of the electrode into the
brain would cause mechanical trauma and trigger both
acute and chronic tissue responses, and the final outcome
depends on factors such as the size, geometry and material of
the probe, the insertion method and the period after inser-
tion.[58] Device implantation could also alter the release of
neurotransmitters and neural activity.[59] While the
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previously developed beta-microprobes were based on a single
pixel scheme that did not provide any spatial information on
the radiotracer distribution,[56] a new wireless probe was
recently published, which contains 10 submillimeter pixels
which allows the analysis of the spatial distribution of the
radiotracer within the region of interest in freely moving
rats.[60]
3.2. Ex vivo approaches of target occupancy
measurements
3.2.1. Tissue homogenate method with radiolabeled
tracer
While for in vivo methods both the drug and the tracer are
administered to the living animals, for ex vivo methods the
tracer is added to the collected tissue from the drug-treated
animal, and the amount of radiotracer bound to the target
in the homogenate is measured by liquid scintillation
counting. In this way tracers with unfavorable in vivo
characteristics (e.g. slow equilibrium at target tissue, phar-
macokinetic variability, etc.) can be used and the costs of
developing suitable tracers are reduced and the amount of
tracer can be precisely controlled. However, the values of
target occupancy obtained by this method are highly
dependent on the binding conditions (particularly the
time and temperature of tracer incubation) and tend to
give an underestimation of drug-induced target occupancy.
[61] This is mainly due to the dissociation of the drug
from the receptor during the ex vivo tracer incubation and
the tissue homogenization step, particularly for those drugs
with a fast dissociation rate from the receptor. Therefore, a
short incubation time and a radiotracer with a fast associa-
tion rate are recommended.[62]
3.2.2. Tissue slice autoradiography imaging
The procedures of this method are the same as that with
tissue homogenate method described above, except that the
animal tissue is sectioned into slices and the amount of
radiotracer bound to the target is quantified by autoradio-
graphy. Unlike tissue homogenate, the tissue slice prepara-
tion maintains structural integrity. It offers higher spatial
resolution than PET/SPECT imaging and thus allows the
investigation of anatomical regions that are small in size.
Traditionally, the radioactivity on the slice is captured by
autoradiographic film, which requires a long exposure period
(weeks) and thus is not considered as an efficient screening
method for determining the target occupancy of compounds.
[62] The introduction of storage phosphor imaging is a
major improvement in ex vivo receptor autoradiography,
which shortens the exposure time from weeks to days or
even 1 day.[63] An alternative method is to use a beta-imager
which uses a highly sensitive gaseous detector of beta parti-
cles. This allows the exposure time to be shortened to a few
hours.[64]
4. Comparison of in vitro and in/ex vivo
measurements of binding kinetics
To investigate whether the current in vitro and in vivo
measurements of binding kinetics deliver similar or transla-
table values, we performed a literature survey to identify
compounds for which both in vitro and in vivo estimates of
target association or dissociation rates were available. Since in
vivo estimates are the least available, we started our search
with in vivo estimates and continued to search for in vitro
estimates of the same compounds. Since the number of
compounds for which we could find in vitro and in vivo
estimates of their target binding kinetics was very low, we
decided to list all estimates we could find and discuss the
reliability and comparability of the estimates below. The
results of this search are listed in Table 3.
Based on Table 3, we can start to answer our first
question:
● What is the relation between in vitro measured binding
kinetics and in vivo measured binding kinetics?
From the results in Table 3, it can be directly seen that
the difference between in vitro and in vivo estimates of
target dissociation rates can be quite substantial (up to 30-
fold) and inconsistent (the ratio varies from 0.2 to 31).
This clearly indicates that the use of in vitro measured
target binding kinetics to predict in vivo binding profiles
is not straightforward. Apart from the studies in Table 3,
another study was published in which no in vivo values
for kon and koff were included, but in vitro values were
used to predict target occupancy profiles of the CRF1
receptor in rats for several antagonists.[23] Although the
in vivo results were not highly informative for the identi-
fication of the binding kinetics for some compounds in
this study, the target occupancy profiles could be pre-
dicted reasonably well.
To investigate the origin of the observed difference
between in vitro and in vivo binding studies, the experimental
details need to be taken into account to identify which results
are less reliable or comparable.
4.1. Temperature
First, all in vitro estimates of association and dissociation rates
which are not obtained at 37°C cannot be compared directly
to in vivo estimates, since these rates are temperature depen-
dent in a compound-specific manner.[86–88] Therefore
entries 3, 9, 12, 13, 17, 18 and 19 in Table 3 cannot be
used to compare in vitro and in vivo dissociation rates.
4.2. Influence of in vivo displacer/competitor dose
Another important factor in the comparison between in vitro
and in vivo estimates of target dissociation rates is the method
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by which the dissociation is induced. Drug-target dissociation
can be induced in in vitro studies either by continuous wash-
ing, the so-called “infinite dilution” method, or by displace-
ment of the drug by adding an excess of a competing ligand.
These methods can give quite different results since washing
cannot displace all free ligand molecules and diffusion-limited
binding (or “rebinding”) can occur. Thus, comparisons
between in vitro and in vivo estimates should use the same
method of dissociation measurement.[19] However, in the in
vivo setting, continuous washing cannot be applied and the
amount of competing compound which can be added is
limited by its toxicological effects. In the analysis of in vivo
drug-target binding studies, computational models can be used
to correct for remaining drug concentrations or partial displa-
cement. However, this is often not done and assumptions have
to be made about the effect of a displacer dose or of a
remaining drug concentration. For entries 1, 3, 4, 8 and 10
in Table 3, the rationale for the displacer dose was not clear,
and model-based analysis was not used. These entries should
therefore not be used to compare in vitro and in vivo dissocia-
tion rates. For entry 1, the in vitro experiment did not use
either a displacer or continuous washing, which makes it even
less appropriate for comparison with the in vivo experiment.
For entries 14–19 in Table 3, the in vivo drug-target
binding kinetic parameters are estimated from PK and PD
data without target occupancy measurements. This makes
these estimates indirect and subject to influences of signal
transduction kinetics and other factors between PK and PD.
Therefore, entries 14–19 cannot be used for a direct compar-
ison of in vitro and in vivo binding kinetic parameters.
4.3. Most valid comparisons
To evaluate the difference between in vitro and in vivo
estimates of association and dissociation rates, we should
only use the most valid comparisons, restricting Table 3 to
entries 2, 5, 6, 7 and 11. Now the ratio between in vitro and
in vivo estimates varies between 0.9 and 4 which is consider-
ably better, but based only on four compounds and two
targets. Moreover, it should be noted that these entries
include only one entry for which the comparison is made
with human binding data. Also, all observations in Table 3
originate from GPCRs and, therefore, none of the studies
used isolated receptors. One could speculate that the correla-
tion between in vitro and in vivo estimates is better for
membrane-bound targets than for soluble targets since the
membrane-bound receptors are mostly measured in mem-
brane fractions and therefore retain some of their natural
environment, whereas soluble targets can be completely pur-
ified. However, the natural exposure of membrane-bound
receptors to the differential composition of extracellular and
intracellular fluids cannot be reproduced in homogenized in
vitro experiments, while the homogeneous environment of
soluble targets can be replicated in vitro.
4.4. Summary
The amount of available literature data to compare in vitro
and in vivo estimates for drug-target dissociation rates in a
valid manner is too low to draw general conclusions about
the predictive value of the in vitro drug-target dissociation
estimates. This is even more so for drug-target association
rates. Moreover, differences in experimental approach and
conditions and differences in data analysis hamper the
comparison of in vitro and in vivo binding kinetics data.
These differences include most frequently a difference in
temperature (i.e. in vitro experiment not at 37°C), differ-
ence in dissociation method (washout vs. displacement)
and analysis method (model-based parameter estimation
vs. graphical methods). Therefore, the current in vitro
estimates of drug-target binding kinetics cannot be trans-
lated reliably into in vivo binding kinetics due to a lack of
available information on comparability and due to metho-
dological differences between in vitro and in vivo
experiments.
5. Missing links in the translation between in vitro
and in vivo binding kinetics
The differential results that have been observed from in
vitro and in vivo studies can be explained by a multitude
of differences between the extremely complex in vivo situa-
tion and the much more simplified in vitro environment.
Possible explanations include factors that are poorly under-
stood, such as the in vivo occurrence of complicated ligand
interactions with multiple targets, allosteric binding sites,
exosites and subcellular compartments or organelles, but
also complex target interactions with other proteins
(homo- and heterodimerization), and other cell membrane
and intra- and extracellular fluid constituents, such as ions.
Moreover, the in vivo three-dimensional structure of multi-
ple cell types is rarely replicated in vitro and unknown
contributors to the observed in vivo target binding kinetics
cannot be excluded.
However, the following section is focused on the better
understood contributors to in vivo target binding kinetics
and how these can be accounted for in the design and
analysis of both in vitro and in vivo experiments
5.1. Experimental conditions in in vitro and in vivo
studies of binding kinetics
As described in the previous section, the comparison of in
vitro and in vivo binding kinetic parameters is often ham-
pered by differential experimental conditions between in vitro
and in vivo studies. We discuss here the most relevant experi-
mental conditions which can hamper the translation between
in vitro and in vivo measured binding kinetics. These are: in
vitro temperature, in vivo displacement method and the pre-
sence of endogenous ligand.
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5.1.1. Temperature
One very important in vitro and ex vivo experimental condi-
tion is the temperature. Since both drug-target association
and dissociation rates are temperature dependent in a com-
pound-specific manner [86–88], translation of binding
kinetics from one temperature to another temperature cannot
be done unless the temperature dependency has been deter-
mined for that specific compound. Moreover, since the target
conformation might be temperature dependent as well, the
Arrhenius plots of kon and koff are not necessarily linear. A
few literature examples are available of linear Arrhenius plots
for kon and koff.[88–90] Therefore, it is highly relevant to
obtain in vitro binding parameters at 37°C, or to obtain a
linear Arrhenius plot at lower temperatures.
5.1.2. Displacer/competitor
Another condition that may affect translational success is the
presence or absence of a displacer/competitor. To account for
this, it is necessary to obtain both in vitro and in vivo
estimates for koff in the presence of a displacer. If both
experiments are done in the absence of a displacer, transla-
tion can still be hampered because of differential diffusion
rates and target clustering in the two experiments, leading to
different diffusion-limited binding (“rebinding”).
5.1.3. Endogenous ligand
The presence of an endogenous ligand is also influencing the
rates of drug-target association and dissociation. An endo-
genous ligand can be present both in vitro and in vivo. To
enable an accurate in vivo and in vitro estimation of drug-
target kon and koff in the presence of an endogenous ligand,
the concentration profile over time during the experiment
and the binding kinetics of the endogenous ligand need to be
known.
5.2. Integrated analysis of multiple determinants of in
vivo target occupancy and drug effect
In order to use in vitro binding kinetic data to predict in vivo
target occupancy and effect kinetics, all kinetic processes
which influence the in vivo kinetics of drug effect need to
be taken into account (see also Section 7). These include
pharmacokinetics, endogenous competition, diffusion-
limited binding, nonspecific binding, target turnover and
signal transduction. Each of these processes will be discussed
in the following sections.
5.2.1. Pharmacokinetics
One of the clearest examples for the need to integrate all
kinetic processes for the prediction of in vivo target occupan-
cies is the role of pharmacokinetics: If the drug concentration
in the human body has a constant profile, an equilibrium
situation will be reached and a slow dissociation rate will not
prolong the target occupancy anymore. On the basis of a very
simple relation between pharmacokinetics and binding
kinetics, one can expect a slow dissociation rate to be
prolonging target occupancy only when its dissociation rate
is slower than its elimination rate (Figure 2, upper panels).
[15,19] However, this might be an oversimplification, and
other processes need to be integrated as well.[19]
5.2.2. Endogenous competition
Another process which is important for the role of binding
kinetics is endogenous competition. The presence of a
varying concentration of endogenous ligand can make a
drug’s binding kinetics more important, also when its
dissociation half-life does not exceed its plasma elimination
half-life (Figure 1).[14,18,91–93] Since endogenous
ligands usually have a varying concentration, endogenous
competition might be relevant for the binding kinetics of
most agonists and antagonists. A hypothesis in this direc-
tion was already published by Kapur and Seeman before
the recent interest in binding kinetics.[93] In their pub-
lication, fast dissociating dopamine antagonists were sug-
gested to be less resistant to dopamine signaling, thereby
preventing side effects from over-suppression of dopamine
signaling.
5.2.3. Diffusion-limited binding
A kinetic process which has got only limited attention for its
effect on target occupancy profiles is diffusion-limited bind-
ing. If the effective diffusion of a drug around its target is
limited, the chance that it will re-associate to its target before
diffusing into the tissue (often called “rebinding”) will
increase and thus the target occupancy will decrease slower
than expected from its binding kinetics and tissue concentra-
tion. Although the possible significance of diffusion and
0
20
40
60
0 2 4 6 8
Time (seconds)
TO
 (%
)
Figure 1. The influence of drug-target binding kinetics on
drug (dashed lines) and dopamine (solid lines) target occu-
pancy (TO) is influenced by endogenous competition, as
simulated by Vauquelin et al.[18] A constant drug concen-
tration and pulsatile dopamine concentration are used, and
the system is allowed to reach equilibrium before t = 0. The
dopamine concentrations rise after 4 s to represent a high
activity period. The drug target dissociation rate (koff)
changes from 181 min−1 (green) to 6.03 min−1 (red), and
0.181 min−1 (black).
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diffusion-limited binding (or “rebinding”) has already been
indicated in studies with rats, humans and in vitro over three
decades ago [9,10,94], there is no general practice of taking
this into account in either in vitro or in vivo studies. As
reported several times by Vauquelin and his colleagues,
based on literature, experimental and theoretical findings,
“rebinding” can have a significant impact on the estimated
koff value in in vitro and in vivo studies, and therefore needs
to be taken into account in the design and analysis of these
studies (Figure 2).[19,41,95–97]
5.2.4. Nonspecific binding
Another kinetic process which can influence the profile of
target occupancy is nonspecific binding. Nonspecifically
bound drug can act as a reservoir which releases drug
upon decreasing free drug concentrations, thereby decreas-
ing the effective elimination rate. Moreover, if the release
of nonspecifically bound drug is slow, this can become the
rate determining factor for the rate of drug elimination
from either the plasma or the target tissue (Figure 3).
[98,99]
5.2.5. Target turnover
The rate of target synthesis and degradation can also influ-
ence the profile of target occupancy, since the breakdown of
occupied target and synthesis of new (unoccupied) target
decreases the occupied fraction. Thus, target turnover pro-
vides a suitable explanation for the limited duration of the
antiplatelet effect of the irreversible binder aspirin.[1]
Moreover, target synthesis and degradation can be regulated
and can function as feedback mechanisms.[100–104] A high
rate of target turnover can limit the impact of a decreasing
dissociation rate constant and can increase the impact of the
association rate constant (Figure 4).
5.2.6. Signal transduction
Apart from these multiple factors which influence the target
occupancy profiles, another step is required to predict effect
kinetics from target occupancy profiles. To do this, the
kinetics of all signal transduction steps need to be taken
into account. The significance of signal transduction kinetics
with respect to binding kinetics has been indicated by a
simulation study of binding kinetics, enzyme inhibition and
several signal transduction pathways.[17] However, since
signal transduction can have various mechanisms and
includes feedback mechanisms, the influence of signal trans-
duction on the role of drug-target binding kinetics can differ
greatly between targets.
Although the kinetics of signal transduction can be impor-
tant, direct relationships between target occupancy and drug
effect have been characterized for a few targets. However, in
vivo target occupancy and drug effect are rarely measured
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Figure 2. The influence of drug-target binding kinetics on
target occupancy (TO) depends on both pharmacokinetics
and diffusion-limited binding, as simulated by Vauquelin
et al.[19] The drug target dissociation rate (koff) changes
from 83 h−1 (black) to 2.1 h−1 (red), 0.35 h−1 (green), and
0.087 h−1 (orange). The drug elimination rate constant is
0.35 h−1 for the left panel and 0.087 h−1 for the right
panel.
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Figure 3. The target occupancy (TO) profile can be influ-
enced by nonspecific binding of the drug, as simulated for
lipid and protein binding in the brain by Peletier et al.[98]
The drug target dissociation rate constant (koff) is 36 h
−1 for
all lines. For the left panel, the drug-protein dissociation
rate constant changes from 1000 s−1 (black) to 100 s−1
(red), 10 s−1 (green), and 1 s−1 (orange). For the right
panel, the drug-lipid dissociation rate constant changes
from 500 s−1 (black) to 100 s−1 (red) and 20 s−1 (green). The
drug-protein and the drug-lipid affinity change in the same
way as the dissociation rate constants, since both drug-pro-
tein and drug-lipid association rate constants remain
unchanged.
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simultaneously, and mathematical models are often required
to estimate the relationship between target occupancy and
effect from pharmacokinetic and pharmacodynamic data.
One example where in vivo target occupancy and drug effect
were measured simultaneously for the dopamine D2 receptor
demonstrated the typical hyperbolical relationship.[105]
However, linear relationships between target occupancy and
effect have been used by mathematical models as well, for
example to describe drug effect for calcium channel blockers
and DPP-4 inhibitors.[20,26]
5.2.7. Integrated mathematical modeling
To incorporate all the processes as described above for the
prediction of target occupancy and drug effect and to use
these predictions for the selection of the best drug candidates,
quantitative mathematical description and integration of all
these processes is essential.
Mathematical models have made use of drug-target bind-
ing kinetics in the previous decades to describe and predict
the time course of drug effect.[20–26] These mathematical
models most often use differential equations to describe the
rate with which concentrations change, rather than describ-
ing the absolute value of a concentration for any time point.
The use of differential equations requires solving of the
differential equations for each time profile and each initial
value, but it also allows the integration of numerous processes
in a relatively simple way. As an example, the decrease in
drug concentration due to elimination is often described by
an equation like Equation 2, where dC/dt is the change in
drug concentration per time unit, C is the drug concentra-
tion and kel is the elimination rate constant.
dC
dt
¼ kel  C (2)
Equation 2 means that if kel = 0.1 min
−1, for example, the
drug concentration decreases with 10% every minute (if you
solve the equation by taking time steps of 1 minute). For
compartmental models, differential equations are used to
describe the concentration in each compartment, and each
compartment is considered to be homogeneous. For example,
if the distribution of a drug over the body is fast or limited,
the concentration profile of a drug in plasma can often be
described by a one-compartment model with absorption and
elimination. Such a compartmental approach can be used to
describe drug-target binding by adding one or more compart-
ments, which represent the drug-target complex, and assum-
ing homogeneous distribution of the target in one of the
pharmacokinetic compartments. This approach has been
used for the simulations of Figures 1–4, where binding was
simulated from a single compartment for Figures 2 and 4,
from a brain compartment for Figure 3 while a constant
concentration was used for Figure 1. Although these simula-
tions are based on simplifying assumptions such as homo-
geneity, they provide a conceptual insight in the impact of
the described processes on the relation between drug-target
binding kinetics and target occupancy.
A special field where drug-target binding kinetics are taken
into account as standard practice is the field of target-
mediated drug disposition (TMDD). TMDD describes the
pharmacokinetics of drugs (mostly biologicals) which are
distributed and eliminated predominantly when bound to
their target. In this situation, binding kinetics are required
to describe the drugs’ pharmacokinetics, since the pharma-
cokinetics depend on the binding and the dissociation is
often relatively slow.[106–109] Mathematical analysis of a
TMDD model revealed that kon had a more pronounced
impact on the maximal target occupancy than koff.[110]
Another field where drug-target binding kinetics are com-
monly incorporated in mathematical models is in the analysis
of PET data (see Table 3). In all these examples and in the
simulations shown in Figures 1–4, mathematical models have
demonstrated their potential to further our understanding of
the role of drug-target binding kinetics in their complex
physiological context.
6. Conclusion
On the basis of the sparse amount of available literature
estimates for drug-target binding kinetics, no conclusions
can be made on how well in vivo binding kinetics are
reflected in in vitro experiments. Moreover, differences in
conditions, methodology and analysis avoid the comparison
of available in vitro and in vivo estimates in many cases.
Next to the relation between in vitro and in vivo estimates
of binding kinetics, the relation between in vivo binding
kinetics and in vivo target occupancy and effect kinetics is
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Figure 4. The influence of drug-target binding kinetics on
target occupancy (TO) can be influenced by target turnover,
as described by the model of Hong et al. for the antiplatelet
effect of aspirin and ibuprofen.[1] The drug target dissocia-
tion rate (koff) changes from 0 (black line representing
aspirin) to 0.001 h−1 (red), 0.01 h−1 (green), 0.1 h−1 (orange)
and 1 h−1 (blue). The target degradation rate constant (kdeg)
is 0.02 h−1 (as identified for aspirin and ibuprofen) for the
left panel and 0.2 h−1 for the right panel (note the different
time scale). The target synthesis rate constant (ksyn) was
adjusted accordingly to obtain a steady-state target concen-
tration of 25 nM for both panels: ksyn = 25 × kdeg.
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also uncertain. This relation can be influenced by pharmaco-
kinetics, endogenous competition, target tissue diffusion,
nonspecific binding, signal transduction and other factors.
A quantitative integration by means of mathematical models
can greatly enhance our understanding of the role of drug-
target binding kinetics in this context.
This implies that more scientific support is required for
the rational selection and development of drug candidates on
basis of in vitro estimates of drug-target binding kinetics.
7. Expert opinion
The aforementioned determinants of target occupancy are
related to each other, and need to be taken into account in
an integrated manner. The use of compartmental modeling,
as applied commonly in PK/PD modeling, is an important
tool to facilitate the integration of all kinetic processes which
are involved in the generation of drug effect (Figure 5). The
value of such models for all stages of drug discovery and
development is increasingly recognized.[111–113]
The feasibility of such an integrative approach in (the
early phases of) drug discovery and development may seem
limited by its complex and time-consuming nature.
However, it is important to note that some of these kinetic
processes are system-specific processes (e.g. endogenous
competition, target turnover and signal transduction).
These system-specific processes are equal for all new com-
pounds and will not decrease the screening throughput in
drug discovery. The integrated analysis of these system-
specific processes can thus be used to define which drug-
specific kinetic parameters (e.g. drug-target association and
dissociation rates, nonspecific binding rates and pharma-
cokinetic parameters) are most relevant per target/drug
class to screen for. During the drug discovery process,
the screening can start with only the most important
parameter and be gradually extended to the other relevant
parameters to refine the compound selection. The
integrated analysis of all contributors to drug effect will
not only improve compound selection, but it will also
enable drug-candidate optimization on the most relevant
parameters and optimization of drug dosing and sampling
times in (pre)clinical investigations.
7.1. Context-dependency of binding kinetics values
To enable the integrated analysis of the kinetic processes
which determine a drug’s effect kinetics, specific information
on all of these separate processes is required. This urges the
performance of both in vitro and in vivo experiments which
deliver drug- and system-specific parameters for all kinetic
processes. This is necessary to avoid experiments which
inform only on the combined effect of multiple processes
and thus deliver context-dependent information. For exam-
ple, if an in vivo binding study is analyzed to determine only
the rate with which the target occupancy inclines and
declines after a certain dose, process-specific information is
lacking because no specific information is collected about the
pharmacokinetics or binding kinetics. This applies also to in
vitro experiments. If a washout experiment is used to estimate
the dissociation rate without a competing ligand, the
obtained estimate can be a combined parameter for both
dissociation and diffusion, because “rebinding” can occur.
[97] The occurrence of multiple kinetic processes during
one experiment is not necessarily problematic, as long as
the results can be analyzed in a process-specific manner to
enable optimal translation to different experimental or clin-
ical conditions. This type of process-specific analysis can be
obtained by using physiologically based PK/PD models with
process-specific parameters.
7.2. Need for an integrated approach
Although experiments are available and in use to estimate
the rate constants of the aforementioned kinetic processes,
there is hardly any information available about what the
Figure 5. Schematic representation of the interconnected kinetic processes which determine target occupancy and effect
kinetics. The central compartment represents the blood, the target site compartment represents the direct environment
around the target, from where binding occurs.
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relative contribution of each of those processes is in the
determination of target occupancy profiles during the var-
ious scenarios of drug treatment. To enable the prediction
of in vivo target occupancy and effect profiles, integrated
analysis of experimental data and increased theoretical
insight in the role of all contributors to target occupancy
and effect are required. Mathematical models which
describe the mechanisms of all relevant processes can be of
great value to both analyze experimental data and simulate
various cases of drug treatment in a comprehensive and
integrated fashion. Increasing knowledge of the drivers of
drug effect is of critical importance to select the best drug
candidates in drug discovery, to optimize drug therapy in
drug development and improve the health of those in need
of medicines.
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